[Thrombopenia increased by heparin and danaparoid].
Pathogenesis, frequency, and management of heparin-induced thrombocytopaenia are well-known. They may be related with both unfractioned heparin and low-molecular weight heparin. Suspected heparin must be discontinued as soon as the diagnosis is established. Orgaran (danaparoid sodium) may be used for management of patients with heparin-associated thrombocytopaenia but can itself be associated with a thrombocytopaenia. Our case report allows us to catch in mind such a crossed complication.
Département d'anesthésie-réanimation, hôpital Pitié-Salpêtrière, 75013 Paris, France. gilles.godet@psl.ap-hop-paris.fr
G
G
Godet
M
M
Bertrand
E
E
Van de Steen
G
G
Boccara
F
F
Koskas
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects*; D002216:Captopril / Q000627:therapeutic use; D016893:Carotid Stenosis / Q000188:drug therapy*; D002809:Chondroitin Sulfates / Q000009:adverse effects*; D003871:Dermatan Sulfate / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000188:drug therapy; D004338:Drug Combinations; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D020521:Stroke / Q000188:drug therapy / Q000209:etiology; D013921:Thrombocytopenia / Q000139:chemically induced*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D002216:Captopril; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid